查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1468145

2024-2032 年按產品、測試類型、流感類型、最終用戶和地區分類的流感診斷市場報告

Influenza Diagnostics Market Report by Product, Test Type, Type of Flu, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球流感診斷市場規模達到 9.52 億美元。疫苗接種工作的不斷增加、即時檢測的便利性、流感病毒研究的不斷增加以及透過公共衛生計劃提高認知是推動市場發展的一些因素。

流行性感冒，俗稱流感，是一種主要針對呼吸系統的病毒感染，包括鼻子、喉嚨和肺部。流感診斷包括一系列免疫測定測試，旨在識別呼吸道樣本中是否存在甲型和乙型流感病毒核蛋白抗原。可用的診斷選項包括快速抗原檢測、逆轉錄聚合酶鏈反應 (RT-PCR)、免疫螢光測定、血清學和快速分子測定。醫學界依靠這些測試來及時檢測流感株並對其進行分類，以幫助做出有效的治療決策和公共衛生管理。診斷技術的不斷發展和對流感病毒的持續研究提高了這些測試的效率和可靠性。在醫療保健提供者努力應對季節性流感爆發和潛在流行病的同時，準確的診斷仍然是基石，可以實現快速干涉和明智的醫療策略。

全球市場主要是由流感爆發的增加所推動的。與此一致的是，全球對潛在流行病日益成長的擔憂推動了對診斷能力的投資，為市場做出了巨大貢獻。此外，快速的技術創新提高了診斷測試的準確性和速度，對市場產生了積極影響。除此之外，日益增多的公眾意識活動鼓勵更多的人及時進行檢測，從而刺激了市場。此外，不斷增加的醫療保健支出支持先進診斷方法的採用，推動了市場的發展。此外，老年人更容易感染嚴重流感，這增加了對診斷的需求。此外，城市人口的增加導致感染率上升，需要強力的診斷。頻繁的旅行會加速流感的傳播，因此需要有效的診斷。這反過來又為市場提供了眾多機會。

流感診斷市場趨勢/促進因素：

輕鬆獲得醫療保健

輕鬆獲得醫療保健正在刺激市場成長。改善醫療設施的可近性鼓勵個人及時尋求流感感染的診斷檢測。當醫療服務很容易獲得時，人們更傾向於在症狀出現時接受檢測，從而儘早發現並採取適當的干涉措施。這種及時的方法不僅有助於防止病毒傳播，而且有助於改善患者的治療效果。此外，便捷的醫療設施支援採用各種診斷方法，包括即時檢測，無需大量實驗室基礎設施即可快速獲得結果。這種便利的醫療保健環境為診斷製造商、醫療保健提供者和患者創造了有利的生態系統，最終促進市場成長。

多種慢性病盛行率上升

幾種慢性疾病的日益流行正在刺激市場。糖尿病、心血管疾病和呼吸系統疾病等慢性疾病會削弱免疫系統，使人更容易受到嚴重流感感染。隨著受這些慢性病影響的人數增加，對準確和早期流感診斷的需求不斷增加。慢性病患者出現流感併發症的風險較高，因此需要及時檢測並採取量身定做的醫療干預措施。醫療保健提供者優先對這些弱勢群體進行檢測，以減輕潛在的併發症並提供及時的治療。此外，慢性病和流感之間的相互關聯性凸顯了綜合診斷方法的必要性。對已有疾病的個體進行準確的流感診斷使醫療保健專業人員能夠制定治療計劃、有效管理併發症並改善患者的治療效果。隨著慢性病在全球持續增加，對流感診斷的需求成為保障患有基礎疾病的個人健康不可或缺的一部分。這種持續的需求對市場做出了巨大貢獻。

人工智慧快速融合

人工智慧（AI）的快速融合正在對市場產生積極影響。人工智慧技術透過提高流感檢測的準確性、速度和效率，正在徹底改變診斷能力。人工智慧驅動的演算法可以分析來自各種來源的大量資料，包括患者病史、症狀和測試結果，以提供更精確和客製化的診斷見解。這加速了流感病例的識別，從而能夠及時採取醫療干預措施和公共衛生應對措施。機器學習和人工智慧演算法也改進了流感爆發的預測模型。透過分析歷史資料、模式和環境因素，這些技術有助於預測潛在的流感流行，幫助醫療機構有效地準備和分配資源。此外，人工智慧驅動的影像分析有助於評估胸部 X 光片等醫學影像，以識別流感相關併發症並準確監測疾病進展。人工智慧整合的快速發展正在改變診斷格局，為醫療保健專業人員提供先進的工具，以實現更明智的決策和精確的患者護理。這種趨勢對市場貢獻很大。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球流感診斷市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依產品

  • 檢測試劑盒和試劑
    • 市場走向
    • 市場預測
  • 儀器
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：按測試類型

  • 分子診斷測試
    • 市場走向
    • 關鍵環節
      • 聚合酶鍊式反應
      • 等溫核酸擴增試驗
      • 其他分子測試
    • 市場預測
  • 傳統診斷測試
    • 市場走向
    • 關鍵環節
      • 快速流感診斷測試
      • 病毒培養測試
      • 直接螢光抗體測試
      • 血清學測試
    • 市場預測

第 8 章：市場區隔：依流感類型

  • A型流感
    • 市場走向
    • 市場預測
  • B 型流感
    • 市場走向
    • 市場預測
  • C型流感
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按最終用戶

  • 醫院
    • 市場走向
    • 市場預測
  • 診斷實驗室
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Becton Dickinson and Company
    • Coris Bioconcept
    • Danaher Corporation
    • DiaSorin SpA
    • F. Hoffmann-La Roche Ltd (Roche Holding AG)
    • Hologic Inc.
    • Meridian Bioscience Inc.
    • Qiagen NV
    • Quidel Corporation
    • Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.)
    • Siemens Healthineers AG (Siemens AG)
Product Code: SR112024A6053

The global influenza diagnostics market size reached US$ 952.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,594.0 Million by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032. The increasing vaccination efforts, the convenience of point-of-care tests, the rising research into flu viruses, and the growing awareness through public health programs are some of the factors propelling the market.

Influenza, commonly known as the flu, is a viral infection primarily targeting the respiratory system, encompassing the nose, throat, and lungs. Influenza diagnostics encompasses an array of immunoassay tests designed to identify the presence of influenza A and B viral nucleoprotein antigens within respiratory samples. Among the diagnostic options available are rapid antigen testing, reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence assays, serology, and rapid molecular assays. The medical fraternity relies on these tests to detect and categorize influenza strains promptly, aiding in effective treatment decisions and public health management. The continual evolution of diagnostic techniques and the ongoing research into influenza viruses enhance the efficiency and reliability of these tests. As healthcare providers strive to combat seasonal flu outbreaks and potential pandemics, accurate diagnostics remain a cornerstone, enabling swift intervention and informed medical strategies.

The global market is majorly driven by the increasing occurrence of flu outbreaks. In line with this, the rising global concerns about potential pandemics drive investments in diagnostic capabilities, significantly contributing to the market. Furthermore, rapid technological innovations improve the accuracy and speed of diagnostic tests, positively influencing the market. Apart from this, the growing public awareness campaigns encourage more individuals to seek timely testing, catalyzing the market. Moreover, the escalating healthcare spending supports the adoption of advanced diagnostic methods, propelling the market. Besides, elderly individuals are more susceptible to severe flu, boosting demand for diagnostics. Additionally, the increasing urban populations contribute to higher infection rates, requiring robust diagnostics. Frequent travel accelerates the spread of the flu, necessitating efficient diagnostics. This, in turn, offers numerous opportunities for the market.

Influenza Diagnostics Market Trends/Drivers:

Easy access to healthcare

The easy access to healthcare is stimulating market growth. Improved accessibility to medical facilities encourages individuals to seek timely diagnostic testing for flu infections. When healthcare services are easily reachable, people are more inclined to undergo testing at the onset of symptoms, leading to early detection and appropriate intervention. This timely approach not only aids in preventing the spread of the virus but also facilitates better patient outcomes. Furthermore, convenient access to healthcare facilities supports the adoption of various diagnostic methods, including point-of-care testing, which provides rapid results without requiring extensive laboratory infrastructure. This accessible healthcare environment creates a favorable ecosystem for diagnostic manufacturers, healthcare providers, and patients, ultimately contributing to market growth.

Increasing prevalence of several chronic diseases

The increasing prevalence of several chronic diseases is catalyzing the market. Chronic diseases, such as diabetes, cardiovascular disorders, and respiratory conditions, weaken the immune system and make individuals more susceptible to severe flu infections. As the number of individuals affected by these chronic conditions rises, the demand for accurate and early influenza diagnostics intensifies. Patients with chronic diseases are at a higher risk of complications from the flu, necessitating prompt detection and tailored medical interventions. Healthcare providers prioritize testing these vulnerable populations to mitigate potential complications and provide timely treatment. Moreover, the interconnectedness of chronic diseases and flu underscores the need for comprehensive diagnostic approaches. Accurate flu diagnosis in individuals with pre-existing conditions enables healthcare professionals to tailor treatment plans, manage complications effectively, and improve patient outcomes. As chronic diseases continue to increase globally, the demand for influenza diagnostics becomes integral in safeguarding the health of individuals with underlying conditions. This ongoing demand significantly contributes to the market.

Rapid integration of artificial intelligence

The rapid integration of artificial intelligence (AI) is favorably impacting the market. AI technologies are revolutionizing diagnostic capabilities by enhancing flu detection accuracy, speed, and efficiency. AI-powered algorithms can analyze vast amounts of data from various sources, including patient histories, symptoms, and test results, to provide more precise and tailored diagnostic insights. This accelerates the identification of flu cases, enabling timely medical interventions and public health responses. Machine learning and AI algorithms also improve predictive modeling for flu outbreaks. By analyzing historical data, patterns, and environmental factors, these technologies aid in forecasting potential flu epidemics, assisting healthcare organizations in preparing and allocating resources effectively. Additionally, AI-driven image analysis assists in evaluating medical images, such as chest X-rays, to identify flu-related complications and monitor disease progression accurately. The rapid pace of AI integration is transforming the diagnostic landscape, offering healthcare professionals advanced tools for more informed decision-making and precise patient care. This trend contributes significantly to the market.

Influenza Diagnostics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global influenza diagnostics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, test type, type of flu and end user.

Breakup by Product:

Test Kit and Reagents

Instruments

Others

Test Kit and Reagents dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes test kit and reagents, instruments, and others. According to the report, test kit and reagents represented the largest segment.

Test kit and reagents form the foundation of diagnostic procedures, providing the necessary chemical components for identifying viral antigens and antibodies in patient samples. These kits enable healthcare professionals to swiftly and accurately diagnose influenza infections, facilitating timely medical interventions and public health responses. The continuous innovation in test kit technology, including improved sensitivity and specificity, contributes to heightened accuracy in flu detection.

On the other hand, instruments encompass the equipment for processing and analyzing samples, automating diagnostic workflows, and delivering reliable results. These instruments, ranging from PCR machines to automated immunoassay platforms, streamline the testing process, reduce human errors, and enhance the overall efficiency of diagnostics.

Breakup by Test Type:

Molecular Diagnostic Tests

Polymerase Chain Reaction

Isothermal Nucleic Acid Amplification Tests

Other Molecular Tests

Traditional Diagnostic Tests

Rapid Influenza Diagnostic Tests

Viral Culture Tests

Direct Fluorescent Antibody Test

Serological Tests

Traditional Diagnostic Test dominates the market

The report has provided a detailed breakup and analysis of the market based on the test type. This includes molecular diagnostic tests (polymerase chain reaction, isothermal nucleic acid amplification tests, other molecular tests) and traditional diagnostic tests (rapid influenza diagnostic tests, viral culture tests, direct fluorescent antibody test, serological tests). According to the report, traditional diagnostic tests represented the largest segment.

Traditional diagnostic tests encompass methods like rapid antigen testing and immunofluorescence assays. While they may not offer the same level of sensitivity as molecular tests, they provide rapid results, making them invaluable in scenarios where swift diagnosis is critical for patient management and public health responses.

Molecular diagnostic tests on the other hand, utilize advanced molecular techniques such as polymerase chain reaction (PCR) and nucleic acid amplification to detect the influenza virus's genetic material directly. These tests offer high sensitivity and specificity, enabling early and accurate identification of viral infections. The increasing adoption of molecular diagnostic tests is driven by their ability to detect multiple flu strains and their potential to differentiate between seasonal and novel influenza viruses.

Breakup by Type of Flu:

Type A Flu

Type B Flu

Type C Flu

Type A Flu dominates the market

The report has provided a detailed breakup and analysis of the market based on the type of flu. This includes type A flu, type B flu, and type C flu. According to the report, type A flu represented the largest segment.

"Type A Flu" includes various influenza viruses, some responsible for seasonal flu outbreaks and potential pandemics. Accurate differentiation of specific Type A strains is essential for targeted treatment and surveillance efforts.

Furthermore, "Type B Flu" encompasses a distinct group of viruses contributing to seasonal flu epidemics. Detecting and categorizing Type B strains aid in tailoring medical interventions and vaccine development to mitigate flu-related complications.

Moreover, "Type C Flu," although typically milder, still requires accurate diagnosis for effective patient management. While it is less likely to cause large outbreaks, its inclusion highlights the comprehensive approach to influenza diagnostics.

Breakup by End User:

Hospitals

Diagnostic Laboratories

Others

Hospitals dominates the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostic laboratories, and others. According to the report, hospitals represented the largest segment.

Hospitals encompass a significant portion of the market demand, offering immediate access to diagnostic services for patients with flu-like symptoms. Timely diagnosis within hospitals enables rapid treatment decisions and infection control measures, which are crucial for managing patient health and preventing virus spread within healthcare facilities.

Furthermore, diagnostic Laboratories are specialized hubs for accurate and thorough flu testing. These laboratories often employ advanced equipment and experienced personnel to conduct comprehensive diagnostic procedures. By focusing on high-quality diagnostics, they support healthcare providers in delivering accurate results, essential for effective patient management and public health interventions.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America's emphasis on research and innovation fosters the development of cutting-edge diagnostic technologies and methodologies. This region leads in adopting advanced testing solutions that enhance the accuracy and efficiency of flu detection. Its high prevalence of chronic diseases and respiratory conditions underscores the need for accurate influenza diagnostics. With a focus on timely detection, healthcare providers in North America rely on a wide range of diagnostic tests to ensure prompt treatment and prevent escalating flu-related complications.

Government initiatives, awareness campaigns, and strong healthcare policies drive the demand for influenza diagnostics. The region's robust public health infrastructure emphasizes the importance of accurate diagnostics in managing seasonal outbreaks and potential pandemics. The prevalence of international travel and globalization also heightens the demand for accurate flu testing in North America, as early detection becomes crucial in preventing the importation and spread of viral strains. The region's commitment to accurate and timely diagnostics positions it as a key driver in shaping the industry's expansion.

Competitive Landscape:

Top companies are bolstering the market through their innovative approaches and expertise. These companies leverage their resources and research capabilities to drive market expansion. They invest significantly in research and development, leading to the creation of advanced diagnostic technologies. These innovations, including AI-powered platforms and rapid testing solutions, enhance the accuracy and efficiency of flu detection. Top companies collaborate with healthcare providers and institutions to ensure widespread product access. These partnerships facilitate the integration of cutting-edge diagnostic solutions into existing healthcare systems, expanding market reach. Moreover, these companies often conduct awareness campaigns to educate healthcare professionals and the public about the importance of timely flu testing. These efforts drive increased demand for accurate diagnostics. Furthermore, their global presence and distribution networks enable them to provide essential diagnostic tools to regions with varying levels of healthcare infrastructure, contributing to overall market growth.

The report has provided a comprehensive analysis of the competitive landscape in the influenza diagnostics market. Detailed profiles of all major companies have also been provided.

Abbott Laboratories

Becton Dickinson and Company

Coris Bioconcept

Danaher Corporation

DiaSorin S.p.A.

F. Hoffmann-La Roche Ltd (Roche Holding AG)

Hologic Inc.

Meridian Bioscience Inc.

Qiagen N.V

Quidel Corporation

Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.)

Siemens Healthineers AG (Siemens AG).

Recent Developments:

In August 2020, Abbott launched the BinaxNOW COVID-19 Ag Card, a rapid antigen test for detecting SARS-CoV-2, the virus causing COVID-19.

In August 2020, BD received Emergency Use Authorization from the FDA for a rapid point-of-care antigen test to detect SARS-CoV-2, providing results in 15 minutes.

In April 2020, Cepheid, a subsidiary of Danaher, received FDA Emergency Use Authorization for its Xpert Xpress SARS-CoV-2 test, designed to deliver rapid results for detecting COVID-19.

Key Questions Answered in This Report

  • 1. What was the size of the global influenza diagnostics market in 2023?
  • 2. What is the expected growth rate of the global influenza diagnostics market during 2024-2032?
  • 3. What are the key factors driving the global influenza diagnostics market?
  • 4. What has been the impact of COVID-19 on the global influenza diagnostics market?
  • 5. What is the breakup of the global influenza diagnostics market based on the product?
  • 6. What is the breakup of the global influenza diagnostics market based on the test type?
  • 7. What is the breakup of the global influenza diagnostics market based on type of flu?
  • 8. What is the breakup of the global influenza diagnostics market based on the end user?
  • 9. What are the key regions in the global influenza diagnostics market?
  • 10. Who are the key players/companies in the global influenza diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Influenza Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Test Kit and Reagents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Test Type

  • 7.1 Molecular Diagnostic Tests
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Polymerase Chain Reaction
      • 7.1.2.2 Isothermal Nucleic Acid Amplification Tests
      • 7.1.2.3 Other Molecular Tests
    • 7.1.3 Market Forecast
  • 7.2 Traditional Diagnostic Tests
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Rapid Influenza Diagnostic Tests
      • 7.2.2.2 Viral Culture Tests
      • 7.2.2.3 Direct Fluorescent Antibody Test
      • 7.2.2.4 Serological Tests
    • 7.2.3 Market Forecast

8 Market Breakup by Type of Flu

  • 8.1 Type A Flu
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Type B Flu
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Type C Flu
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostic Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Becton Dickinson and Company
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Coris Bioconcept
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Danaher Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 DiaSorin S.p.A.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd (Roche Holding AG)
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 Hologic Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Meridian Bioscience Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Qiagen N.V
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Quidel Corporation
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.)
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
    • 15.3.12 Siemens Healthineers AG (Siemens AG)
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Influenza Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Influenza Diagnostics Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Influenza Diagnostics Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Influenza Diagnostics Market: Breakup by Test Type (in %), 2023
  • Figure 6: Global: Influenza Diagnostics Market: Breakup by Type of Flu (in %), 2023
  • Figure 7: Global: Influenza Diagnostics Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Influenza Diagnostics Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Influenza Diagnostics (Test Kit and Reagents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Influenza Diagnostics (Test Kit and Reagents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Influenza Diagnostics (Instruments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Influenza Diagnostics (Instruments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Influenza Diagnostics (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Influenza Diagnostics (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Influenza Diagnostics (Molecular Diagnostic Tests) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Influenza Diagnostics (Molecular Diagnostic Tests) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Influenza Diagnostics (Traditional Diagnostic Tests) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Influenza Diagnostics (Traditional Diagnostic Tests) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Influenza Diagnostics (Type A Flu) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Influenza Diagnostics (Type A Flu) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Influenza Diagnostics (Type B Flu) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Influenza Diagnostics (Type B Flu) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Influenza Diagnostics (Type C Flu) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Influenza Diagnostics (Type C Flu) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Influenza Diagnostics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Influenza Diagnostics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Influenza Diagnostics (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Influenza Diagnostics (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Influenza Diagnostics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Influenza Diagnostics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: North America: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: North America: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: United States: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: United States: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Canada: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Canada: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Asia-Pacific: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Asia-Pacific: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: China: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: China: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Japan: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Japan: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: India: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: India: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: South Korea: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: South Korea: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Australia: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Australia: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Indonesia: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Indonesia: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Others: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Others: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Europe: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Europe: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Germany: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Germany: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: France: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: France: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: United Kingdom: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: United Kingdom: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Italy: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Italy: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Spain: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Spain: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Russia: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Russia: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Latin America: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Latin America: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Brazil: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Brazil: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Mexico: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Mexico: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Middle East and Africa: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Middle East and Africa: Influenza Diagnostics Market: Breakup by Country (in %), 2023
  • Figure 79: Middle East and Africa: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Global: Influenza Diagnostics Industry: SWOT Analysis
  • Figure 81: Global: Influenza Diagnostics Industry: Value Chain Analysis
  • Figure 82: Global: Influenza Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Influenza Diagnostics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Influenza Diagnostics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Influenza Diagnostics Market Forecast: Breakup by Test Type (in Million US$), 2024-2032
  • Table 4: Global: Influenza Diagnostics Market Forecast: Breakup by Type of Flu (in Million US$), 2024-2032
  • Table 5: Global: Influenza Diagnostics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Influenza Diagnostics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Influenza Diagnostics Market: Competitive Structure
  • Table 8: Global: Influenza Diagnostics Market: Key Players